Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
20.1M
-
Number of holders
-
19
-
Total shares
-
649K
-
Shares change
-
+241K
-
Total reported value, excl. options
-
$2.68M
-
Value change
-
+$950K
-
Number of buys
-
12
-
Number of sells
-
-4
-
Price
-
$4.11
Significant Holders of Elicio Therapeutics, Inc. - Common Stock, par value $0.01 per share (ELTX) as of Q2 2024
filings reported holding ELTX - Elicio Therapeutics, Inc. - Common Stock, par value $0.01 per share as of Q2 2024.
Elicio Therapeutics, Inc. - Common Stock, par value $0.01 per share (ELTX) has 19 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 649K shares
of 20.1M outstanding shares and own 3.23% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (226K shares), ARMISTICE CAPITAL, LLC (100K shares), GEODE CAPITAL MANAGEMENT, LLC (71.5K shares), Arena Investors LP (50K shares), CM Management, LLC (50K shares), Hudson Bay Capital Management LP (48.7K shares), STATE STREET CORP (21.9K shares), BlackRock Inc. (19K shares), MEYER HANDELMAN CO (13.9K shares), and BRIDGEWAY CAPITAL MANAGEMENT, LLC (12.5K shares).
This table shows the top 19 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.